Article

TB4 can protect cornea against oxidative damage

Administering TB4 (Thymosin Beta 4, RegeneRx) up-regulates anti-oxidative enzymes in human corneal epithelial cells, helping to protect the cornea and resist oxidative damage, according to researchers.

Bethesda, MD-Administering TB4 (Thymosin Beta 4, RegeneRx) up-regulates anti-oxidative enzymes in human corneal epithelial cells, helping to protect the cornea and resist oxidative damage, according to a study done by researchers at the Institute of Biopharmaceutical Science, National Yang-Ming University, Tapei, Taiwan.

The researchers believe that TB4's ability to protect cells against oxidative damage is due to cellular internalization, or the ability to migrate inside cells, which they said is essential for TB4's protective effects.

"This interesting study from an independent research group in Taiwan further expands the research we and others have conducted and shows yet again TB4's effects in protecting and repairing tissues-in this case the cornea," said Gabriel Sosne, MD, PhD, assistant professor of ophthalmology at Wayne State University School of Medicine and the Kresge Eye Institute in Detroit, and a member of the RegeneRx Medical and Scientific Advisory Board.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.